Rhythm Pharmaceuticals, Inc. Common Stock RYTM

Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company engaged in the development and commercialization of therapies for patients with rare neuroendocrine diseases. The company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. In addition, it has two early-stage investigational MC4R agonists in clinical development, RM-718 and bivamelagon, designed not to cause hyperpigmentation. The company is also focused on advancing potential candidates for congenital hyperinsulinism. It currently operates in two business segments: the United States, which generates maximum revenue, and International.

• GlobeNewswire Inc. 4 ago

  Rhythm Pharmaceuticals Announces Preliminary Data from Phase 2 Trial that Showed RM-718 Demonstrated Positive Efficacy Signal in Acquired Hypothalamic Obesity

  Rhythm Pharmaceuticals announced preliminary Phase 2 trial results for RM-718, an investigational MC4R agonist, showing an 11.6% mean BMI reduction in acquired hypothalamic obesity patients at 16 weeks. The efficacy is comparable to existing treatments setmelanotide and bivamelagon, with notably reduced hyperpigmentation side effects (only 2 mild injection site cases). The company will discuss Q2 2026 financial results in a conference call.

  

• GlobeNewswire Inc. 16 jul

  Kuehn Law Encourages Investors of Rhythm Pharmaceuticals, Inc. to Contact Law Firm

  Kuehn Law is investigating whether officers and directors of Rhythm Pharmaceuticals breached fiduciary duties to shareholders through potential self-dealing. Long-term shareholders may be entitled to damages and corporate governance reforms. The law firm is also investigating similar matters at Travere Therapeutics and Viking Therapeutics.

  

• Benzinga 15 jun

  Why Is Rhythm Pharma Stock Jumping Today?

  Rhythm Pharmaceuticals (NASDAQ: RYTM) stock surged 5.47% after presenting six-month Phase 2 trial data for setmelanotide in Prader-Willi syndrome patients. The study showed meaningful improvements in BMI (3.06% mean reduction), body composition, hyperphagia, and behavioral measures, with a consistent safety profile. The trial enrolled 18 patients aged 6-23, with 17 remaining on active treatment.